Pieris Pharmaceuticals Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Pieris Pharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-3.2%

Rückkaufsrendite

Gesamte Aktionärsrendite	-3.2%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

Jul 11

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Apr 21

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Mar 19

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Dec 18

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Aug 18

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

May 15

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Apr 17

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Dec 31

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Aug 10

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Aug 04

Pieris: Early Stage Developer Of Novel Asset Class

Jan 09

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Dec 15

Progress At Pieris Pharmaceuticals

Oct 27

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Aug 05

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 19

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

May 22

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

May 19

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Apr 01

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

Mar 08

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Feb 01

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 28

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Dec 02

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PIRS in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PIRS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Pieris Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PIRS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PIRS)	n/a
Untere 25 % des Marktes (US)	1.3%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (PIRS) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PIRS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PIRS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PIRS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PIRS keine Ausschüttungen gemeldet hat.

Pieris Pharmaceuticals Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Third quarter 2024 earnings released: US$2.19 loss per share (vs US$8.70 loss in 3Q 2023)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Dec 02, 2024

Second quarter 2024 earnings released: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023)

Palvella Therapeutics, Inc. agreed to acquire Pieris Pharmaceuticals, Inc. (NasdaqCM:PIRS) in a reverse merger transaction.

New major risk - Share price stability

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%

First quarter 2024 earnings released: US$3.96 loss per share (vs US$14.15 loss in 1Q 2023)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

New major risk - Share price stability

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

Consensus revenue estimates fall by 31%

Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?

Price target decreased to US$7.00

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Consensus revenue estimates fall by 48%

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 23%

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Pieris: Early Stage Developer Of Novel Asset Class

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Progress At Pieris Pharmaceuticals

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Consensus revenue estimates increase to US$32.5m

Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts

Price target increased to US$8.50

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope

Consensus revenue estimates fall to US$22.0m

Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates

Price target decreased to US$7.50

Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: US$2.41

Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like

New 90-day high: US$3.19

We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Price target raised to US$9.00

How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: US$3.13

How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?

Analysts lower revenue estimates to US$30.5m

Third quarter 2020 earnings released: US$0.26 loss per share

Earnings beat expectations, revenue disappoints

New 90-day low: US$2.33

Analysts increase revenue estimates to US$45.9m